DE69631229T2 - Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum - Google Patents

Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum Download PDF

Info

Publication number
DE69631229T2
DE69631229T2 DE69631229T DE69631229T DE69631229T2 DE 69631229 T2 DE69631229 T2 DE 69631229T2 DE 69631229 T DE69631229 T DE 69631229T DE 69631229 T DE69631229 T DE 69631229T DE 69631229 T2 DE69631229 T2 DE 69631229T2
Authority
DE
Germany
Prior art keywords
antibody solution
antibody
solution
aca
detergent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631229T
Other languages
German (de)
English (en)
Other versions
DE69631229D1 (de
Inventor
William R. Cary Alonso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24120836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69631229(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE69631229D1 publication Critical patent/DE69631229D1/de
Publication of DE69631229T2 publication Critical patent/DE69631229T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69631229T 1995-09-22 1996-09-10 Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum Expired - Lifetime DE69631229T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/532,211 US6686191B1 (en) 1995-09-22 1995-09-22 Preparation of virally inactivated intravenously injectable immune serum globulin
US532211 1995-09-22

Publications (2)

Publication Number Publication Date
DE69631229D1 DE69631229D1 (de) 2004-02-05
DE69631229T2 true DE69631229T2 (de) 2004-12-02

Family

ID=24120836

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631229T Expired - Lifetime DE69631229T2 (de) 1995-09-22 1996-09-10 Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum

Country Status (10)

Country Link
US (1) US6686191B1 (enExample)
EP (2) EP1356829A3 (enExample)
JP (1) JP4036494B2 (enExample)
AT (1) ATE257016T1 (enExample)
AU (1) AU709608B2 (enExample)
CA (1) CA2185859C (enExample)
DE (1) DE69631229T2 (enExample)
DK (1) DK0764447T3 (enExample)
ES (1) ES2213760T3 (enExample)
PT (1) PT764447E (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044948A2 (en) * 1997-04-07 1998-10-15 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
BR9807936A (pt) 1997-04-08 2000-02-22 Baxter Ag Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
US6717116B1 (en) * 1999-08-10 2004-04-06 Ibiden Co., Ltd. Semiconductor production device ceramic plate
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
KR100791502B1 (ko) * 2006-09-29 2008-01-03 한스바이오메드 주식회사 바이러스 불활화된 무세포 인체 이식재 생산방법
EP2077118A1 (en) * 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102357259A (zh) * 2011-07-28 2012-02-22 王珊珊 一种生物蛋白海绵及其制备方法
EP3981873A1 (en) 2012-06-29 2022-04-13 EMD Millipore Corporation Methods for inactivating viruses during a protein purification process
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
EP0523406B1 (en) * 1991-07-05 1998-12-09 Bayer Corporation Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity

Also Published As

Publication number Publication date
EP1356829A2 (en) 2003-10-29
EP0764447B1 (en) 2004-01-02
JP4036494B2 (ja) 2008-01-23
EP0764447A2 (en) 1997-03-26
ATE257016T1 (de) 2004-01-15
AU6569096A (en) 1997-03-27
AU709608B2 (en) 1999-09-02
EP1356829A3 (en) 2003-12-17
CA2185859A1 (en) 1997-03-23
EP0764447A3 (en) 1997-07-30
ES2213760T3 (es) 2004-09-01
PT764447E (pt) 2004-04-30
CA2185859C (en) 2011-04-19
JPH09124507A (ja) 1997-05-13
US6686191B1 (en) 2004-02-03
DE69631229D1 (de) 2004-02-05
DK0764447T3 (da) 2004-05-03

Similar Documents

Publication Publication Date Title
DE69920693T2 (de) Verfahren zur herstellung von immunoglobulinen zur intravenösen verabreichung und anderen immunoglobulin-produkten
DE69225757T2 (de) Lyophilische monoklonale antikörperpräparationen
DE69631229T2 (de) Herstellung von virusinaktivierten intravenös injektierbaren Globulin aus Immunserum
DE69821741T2 (de) Immunoglobulin enthaltende zusammensetzung
DE2801123C2 (de) Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
DE3927111C3 (de) Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
DE69808620T2 (de) Universell verwendbares bluttplasma
EP0122909B1 (de) Immunglobulin-G-hältige Fraktion
DE69120192T2 (de) Verfahren zur Herstellung von sekretorischen Immunoglobulin-A-Präparaten
DE3889938T2 (de) Injizierbare Lösungen von Gamma-Globulin.
CH640140A5 (de) Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin.
DE3786832T2 (de) Verfahren zur Herstellung von Immunoglobulinzubereitungen für intravenöse Injektion.
DE3927112C1 (enExample)
DE2827027B2 (de) Gefriergetrocknetes natives T -globulin-Präparat zur intravenösen Verabreichung
EP0525502B1 (de) Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
EP0085747B2 (de) Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung
EP0247998B1 (de) Verfahren zur Inaktivierung von vermehrungsfähigen filtrierbaren Krankheitserregern
EP0139975A1 (de) Verfahren zur Pasteurisierung von Humanplasma
DE3604947C2 (enExample)
DE60226327T2 (de) Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
DE19600939C1 (de) Verfahren zur Trennung von IgG und IgA
EP1053754A1 (de) Verfahren zur Inaktivierung von Viren
EP0249167B1 (de) Verfahren zur Herstellung einer pasteurisierten Immunglobulinpraeparation
DE1148037B (de) Verfahren zur Herstellung eines desaggregierten, das Komplementsystem nicht beeinflussenden Gammaglobulins
AT367297B (de) Verfahren zur herstellung eines serumeiweiss-pr[parates

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings